Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Streptococcus pneumoniae capsular polysaccharide serotype 6B is a complex carbohydrate polymer that encapsulates the bacterium, serving as its primary virulence factor. This polysaccharide structure protects the pathogen from the host's immune system by inhibiting phagocytosis and preventing complement-mediated lysis. Due to its significant role in causing invasive pneumococcal diseases such as pneumonia, meningitis, and sepsis, it is utilized as a key antigen in various pneumococcal vaccines. These vaccines, including conjugate (PCV) and polysaccharide (PPSV) formulations, trigger the production of specific antibodies that bind to the 6B capsule, allowing for opsonization and subsequent clearance by the host's immune system. Monitoring the efficacy of these interventions typically involves measuring serotype-specific IgG levels and opsonophagocytic activity.
Induction of serotype-specific humoral immunity, specifically opsonophagocytic antibodies that facilitate bacterial recognition and destruction by immune cells.
3 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Streptococcus pneumoniae capsular polysaccharide serotype 6B (CPS 6B).